You are currently viewing Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel

Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel

Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuasca

Vancouver, British Columbia–(Newsfile Corp. – December 21, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in Canada and the United States.

HaluGen’s Psychedelics Genetic Test Kit now includes a key pharmacokinetic biomarker, the CYP2D6 gene. The CYP2D6 ‘poor metabolizer’ gene mutation, carried by approximately five to ten percent of the population, influences the metabolism of LSD, MDMA and ayahuasca, which can cause individuals to metabolize these hallucinogenic drugs up to two times slower than normal. Poor metabolizers can also experience an increased duration, intensity of effect and adverse drug reactions.

HaluGen’s Psychedelics Genetic Test also includes other relevant pharmacodynamic, pharmacokinetic and mental health risk biomarkers including:

  • HTR2A gene – This gene can impact response to serotonin, the “happiness hormone”, which is the primary mechanism of action for psychedelics such as psilocybin, LSD and DMT, for the twenty percent of the population that carry a specific gene variant which influences serotonin receptor density;
  • CYP2B6 gene – This gene can decrease the metabolism of ketamine for the ten to twenty percent of people who carry a specific ‘poor metabolizer’ gene variant; and
  • C4A, NRG1 and DISC1 genes – These genes can influence mental health risk.

Genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy. HaluGen’s psychedelics pre-screening platform provides genetic, personal and familial insights to better inform one’s potential psychedelic experience. By obtaining DNA test results and data from mental-health surveys, individuals are equipped with valuable insights to make more informed decisions around their psychedelic-assisted therapy, potential side effects and risk profile.

For more information on pricing and ordering, please visit HaluGen’s website at

The Company intends to implement genetic testing in its upcoming research initiatives, which include EBIQ-101, an Observational Study that is currently recruiting, and within its EBRX-101 human trial, expected to begin in Q1 of 2021. The data from these initiatives will be used to improve the testing kit and to advance its utility for both consumers and healthcare professionals.

“HaluGen’s expanded Psychedelics Genetic Test Kit continues to build upon the overall potential of Entheon’s personalized tools for use in preparation for psychedelic treatment,” said Timothy Ko, Chief Executive Officer of Entheon. “HaluGen’s test is the most comprehensive genetic pre-screening platform currently available for individuals looking to gain insights into their own experiences and outcomes as they explore the potential for psychedelic therapy.”

About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Entheon is comprised of three divisions, Entheon RX™, focused on the development of therapeutic drugs, using DMT as the pharmacological benchmark; Entheon ID™, focused on identification, analysis and predictive use of EEG biomarkers and genetics in the selection and management of drug treatment; and Entheon IQ™, focused on the development of treatment algorithms through the analysis of patient data. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

About HaluGen Life Sciences Inc.
HaluGen has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, with the goal of improving patient care and reducing side effects and risk. HaluGen’s genetic-based psychedelic pre-screening platform helps evaluate an individual’s overall sensitivity and risk profile when using hallucinogenic drugs. This platform is the first of its kind with test results within days.

For more information, please contact the Company at:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615

For sales & marketing inquiries, please contact the Company at:
Entheon Biomedical Corp.
Ryan McCreanor, HaluGen/Lobo Genetics Business Development Manager
Telephone: +447921886252

For media inquiries, please contact Elizabeth Glassen of BlueSky Communications at:
BlueSky Communications
Elizabeth Glassen, Account Manager
Telephone: +1 (647) 309-0141

Cautionary Note on Forward-Looking Information

This news release includes certain forward-looking statements and forward-looking information (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, statements with respect to HaluGen’s genetic testing kit, potential market, generation of revenue by the Company if any, the efficacy of the products, and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward-looking information can be identified by words such as “pro forma”, “plans”, “expects”, “will”, “may”, “should”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the Company being able to follow through with anticipated business plans and timing of future activities of the Company, expected sales of HaluGen’s Psychedelics Genetic Test, the ability of the Company to obtain sufficient financing to fund its business activities and plans, delays in obtaining regulatory approvals (including of the Canadian Securities Exchange), changes in laws, regulations and policies affecting the Company’s operations and the Company’s limited operating history.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this presentation or incorporated by reference herein, except as otherwise required by law.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.